Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/221578
Non-neutralizing anti-type I interferon autoantibodies could increase thrombotic risk in critical COVID-19 patients
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
During the COVID-19 pandemic, approximately 15% of patients with severe COVID-19 pneumonia were reported to have neutralizing anti-type I interferon (IFN) autoantibodies, which impaired the antiviral response and led to a poorer prognosis. However, the physiological impact of non-neutralizing autoantibodies remains unclear. In our cohort of COVID-19 patients admitted to intensive care, the presence of non-neutralizing anti-type I IFN autoantibodies increased the risk of thrombotic complications, likely via a cytokine carrier mechanism, prolonging the half-life of cytokines and dysregulating vascular endothelial function. Previous studies have associated non-neutralizing anti-type I IFN autoantibodies with an increased risk of cardiovascular complications in autoimmune diseases like systemic lupus erythematosus, but their relevance in infectious diseases remains uncertain. Stratifying anti-type I IFN autoantibodies based on their neutralizing capacity may have clinical significance not only in terms of susceptibility to infectious diseases but also in predicting cardiovascular and thrombotic events.
Subject
Subject (English)
Citation
Citation
FRAMIL, Mario, et al. Non-neutralizing anti-type I interferon autoantibodies could increase thrombotic risk in critical COVID-19 patients. Frontiers in Immunology. 2025. Vol. 16. ISSN 1664-3224. [consulted: 9 of June of 2026]. Available at: https://hdl.handle.net/2445/221578